Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eli Lilly and Company

https://www.lilly.com/

Latest From Eli Lilly and Company

Pemaryze Wins Cost-Effectiveness Thumbs Up For Rare Bile Duct Cancer In England

Bavencio, Taltz, Cosentyx, and Opdivo plus Yervoy were this week also the subject of final recommendations from the health technology assessment body, NICE, on whether or not they should be used on the National Health Service for certain indications.

United Kingdom Health Technology Assessment

Arvinas, Pfizer Partner To Pursue Best-In-Class Breast Cancer Strategy

Pfizer agreed to pay up to $2.4bn to share development and commercialization costs for Arvinas’ estrogen receptor degrader, including in combination with Ibrance.

Deals Cancer

Interchangeable Biosimilars: Insulin Likely First But Humira May Be More Important Precedent

US FDA’s first decision on biosimilars interchangeability might have less meaning for two insulin products, but payer and prescriber responses to interchangeable biosimilars for adalimumab, which are further out on the horizon, may be more instructive regarding the importance of interchangeability status.

Biosimilars Reimbursement

EU Decision Time On Broader Indication For AbbVie’s Skyrizi

The European Medicines Agency is meeting this week to consider applications to broaden the use of approved drugs to include new indications in the EU. 

Drug Review Regulation
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Alnara Pharmaceuticals, Inc.
    • ARMO BioSciences, Inc.
    • Applied Molecular Evolution
    • Avid Radiopharmaceuticals, Inc.
    • Bowfin Acquisition Corporation
    • Class AP
    • CoLucid Pharmaceuticals, Inc.
    • Dermira Inc.
    • Disarm Therapeutics, Inc.
    • Hypnion
    • ICOS Corporation
    • ImClone Systems
    • Loxo Oncology, Inc. (LOXO)
    • Protomer Technologies
    • SGX Pharmaceuticals (Structural GenomiX)
    • Valocor Therapeutics, Inc.
UsernamePublicRestriction

Register